Full Press Release Details
Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statements of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
| As at | Note | March 31, 2026 | December 31, 2025 | ||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | 213,404 | 252,243 | |||||
| Restricted cash | 20,124 | 20,081 | |||||
| Marketable securities | 139 | 84 | |||||
| Accounts receivable | 29,059 | 27,643 | |||||
| Biological assets | 6 | 2,969 | 3,120 | ||||
| Inventory | 7 | 134,982 | 126,877 | ||||
| Prepaid expenses and deposits | 15,158 | 15,566 | |||||
| Investments | 12 | 362 | 484 | ||||
| Assets held for sale | 746 | 746 | |||||
| Net investment in subleases | 10 | 2,877 | 2,775 | ||||
| 419,820 | 449,619 | ||||||
| Non-current assets | |||||||
| Long-term deposits and receivables | 2,508 | 4,526 | |||||
| Right of use assets | 8 | 136,852 | 138,353 | ||||
| Property, plant and equipment | 9 | 149,398 | 151,900 | ||||
| Net investment in subleases | 10 | 11,244 | 11,643 | ||||
| Intangible assets | 11 | 57,824 | 58,520 | ||||
| Investments | 12 | 14,322 | 11,574 | ||||
| Equity-accounted investees | 13 | 395,411 | 385,534 | ||||
| Goodwill | 127,260 | 124,248 | |||||
| Total assets | 1,314,639 | 1,335,917 | |||||
| Liabilities | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | 51,799 | 56,747 | |||||
| Lease liabilities | 14 | 34,990 | 35,462 | ||||
| 86,789 | 92,209 | ||||||
| Non-current liabilities | |||||||
| Lease liabilities | 14 | 133,381 | 134,471 | ||||
| Other liabilities | 6,925 | 8,041 | |||||
| Total liabilities | 227,095 | 234,721 | |||||
| Shareholders' equity | |||||||
| Share capital | 15(b) | 2,274,393 | 2,310,398 | ||||
| Warrants | 306 | 306 | |||||
| Contributed surplus | 53,089 | 54,038 | |||||
| Accumulated deficit | (1,282,860 | ) | (1,302,441 | ) | |||
| Accumulated other comprehensive income ( AOCI ) | 42,616 | 38,895 | |||||
| Total shareholders' equity | 1,087,544 | 1,101,196 | |||||
| Total liabilities and shareholders' equity | 1,314,639 | 1,335,917 |
Commitments and contingencies (note 23)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
| Three months ended March 31 | ||||||||||
| Note | 2026 | 2025 | ||||||||
| Net revenue | 17 | 195,906 | 204,914 | |||||||
| Cost of sales | 7 | 143,094 | 148,273 | |||||||
| Gross profit | 52,812 | 56,641 | ||||||||
| Investment income | 18 | 1,537 | 2,856 | |||||||
| Share of profit (loss) of equity-accounted investees | 13 | 501 | (4,457 | ) | ||||||
| General and administrative | 46,607 | 46,359 | ||||||||
| Sales and marketing | 4,009 | 3,767 | ||||||||
| Depreciation and amortization | 8,9,11 | 12,855 | 13,228 | |||||||
| Share-based compensation | 16 | 616 | 1,388 | |||||||
| Restructuring costs | 172 | 326 | ||||||||
| Asset (reversal) impairment, net | 8,9 | (178 | ) | 1,984 | ||||||
| Other income | (81 | ) | ||||||||
| Research and development | 4 | 100 | ||||||||
| Gain on disposition of assets | (40 | ) | (59 | ) | ||||||
| Operating loss | (9,114 | ) | (12,053 | ) | ||||||
| Other expenses, net | 19 | (2,294 | ) | (2,654 | ) | |||||
| Loss before income tax | (11,408 | ) | (14,707 | ) | ||||||
| Income tax recovery | 1,497 | |||||||||
| Net loss | (9,911 | ) | (14,707 | ) | ||||||
| Equity-accounted investees - share of other comprehensive income (loss) | 13 | 5,013 | (348 | ) | ||||||
| Investments at fair value through other comprehensive income ( FVOCI ) - change in fair value | 12 | (1,292 | ) | (5,230 | ) | |||||
| Comprehensive loss | (6,190 | ) | (20,285 | ) | ||||||
| Net loss per common share attributable to owners of the Company | ||||||||||
| Basic and diluted | 21 | $ | (0.04 | ) | $ | (0.06 | ) |
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
| Accumulated other comprehensive income | ||||||||||||||||||||||
| Note | Share capital | Warrants | Contributed surplus | Accumulated deficit | Equity-accounted investees | Investments at FVOCI | Total | |||||||||||||||
| Balance at December 31, 2025 | 2,310,398 | 306 | 54,038 | (1,302,441 | ) | 31,673 | 7,222 | 1,101,196 | ||||||||||||||
| Net loss | (9,911 | ) | (9,911 | ) | ||||||||||||||||||
| Other comprehensive income (loss) | 5,013 | (1,292 | ) | 3,721 | ||||||||||||||||||
| Share repurchases | 15(b) | (38,760 | ) | 29,492 | (9,268 | ) | ||||||||||||||||
| Share-based compensation | 16 | 1,806 | 1,806 | |||||||||||||||||||
| Employee awards exercised | 2,755 | (2,755 | ) | |||||||||||||||||||
| Balance at March 31, 2026 | 2,274,393 | 306 | 53,089 | (1,282,860 | ) | 36,686 | 5,930 | 1,087,544 |
| Balance at December 31, 2024 | 2,346,728 | 667 | 57,156 | (1,323,965 | ) | 50,906 | 1,864 | 1,133,356 | ||||||||||||||
| Net loss | (14,707 | ) | (14,707 | ) | ||||||||||||||||||
| Other comprehensive loss | (348 | ) | (5,230 | ) | (5,578 | ) | ||||||||||||||||
| Share repurchases | (51,714 | ) | 36,383 | (15,331 | ) | |||||||||||||||||
| Share-based compensation | 16 | 2,459 | 2,459 | |||||||||||||||||||
| Employee awards exercised | 93 | (93 | ) | |||||||||||||||||||
| Balance at March 31, 2025 | 2,295,107 | 667 | 59,522 | (1,302,289 | ) | 50,558 | (3,366 | ) | 1,100,199 |
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
| Three months ended March 31 | ||||||||||
| Note | 2026 | 2025 | ||||||||
| Cash provided by (used in): | ||||||||||
| Operating activities | ||||||||||
| Net loss for the period | (9,911 | ) | (14,707 | ) | ||||||
| Adjustments for: | ||||||||||
| Income tax recovery | (1,497 | ) | ||||||||
| Interest and fee income | 18 | (1,482 | ) | (2,856 | ) | |||||
| Change in fair value of biological assets | 6 | (46 | ) | (1,447 | ) | |||||
| Change in fair value of inventory sold | 230 | 336 | ||||||||
| Share-based compensation | 16 | 616 | 1,388 | |||||||
| Depreciation and amortization | 8,9,11 | 14,116 | 14,187 | |||||||
| Gain on disposition of assets | (40 | ) | (59 | ) | ||||||
| Inventory impairment and obsolescence | 7 | 1,446 | 591 | |||||||
| Finance costs, net | 19 | 2,062 | 1,690 | |||||||
| Change in estimate of fair value of derivative warrants | (12 | ) | ||||||||
| Unrealized foreign exchange (gain) loss | (299 | ) | 13 | |||||||
| Asset (reversal) impairment, net | 8,9 | (178 | ) | 1,984 | ||||||
| Share of (profit) loss of equity-accounted investees | 13 | (501 | ) | 4,457 | ||||||
| Unrealized gain on marketable securities | 18 | (206 | ) | |||||||
| Additions to marketable securities | 151 | |||||||||
| Interest received | 1,361 | 2,936 | ||||||||
| Exercise of cash-settled deferred share units | 16(d) | (474 | ) | |||||||
| Change in non-cash working capital | 3,20 | (1,867 | ) | (713 | ) | |||||
| Net cash provided by operating activities | 3,481 | 7,788 | ||||||||
| Investing activities | ||||||||||
| Additions to property, plant and equipment | 9 | (2,638 | ) | (1,588 | ) | |||||
| Additions to investments | 12 | (4,032 | ) | (8,997 | ) | |||||
| Principal payments from investments | 12 | 116 | 26,907 | |||||||
| Capital (contributions) distributions from equity-accounted investees | 13 | (2,866 | ) | 719 | ||||||
| Proceeds from disposal of property, plant and equipment | 43 | 113 | ||||||||
| Acquisitions | 4 | (2,900 | ) | |||||||
| Change in non-cash working capital | 20 | 911 | 18 | |||||||
| Net cash (used in) provided by investing activities | (11,366 | ) | 17,172 | |||||||
| Financing activities | ||||||||||
| Payments on lease liabilities, net | 10,14 | (10,056 | ) | (7,512 | ) | |||||
| Repurchase of common shares | 15(b) | (9,575 | ) | (15,031 | ) | |||||
| Change in non-cash working capital | 20 | 819 | 91 | |||||||
| Net cash used in financing activities | (18,812 | ) | (22,452 | ) | ||||||
| Change in cash and cash equivalents | (26,697 | ) | 2,508 | |||||||
| Adjustment on initial application of amendments to IFRS 9 on January 1, 2026 | (12,142 | ) | ||||||||
| Cash and cash equivalents, beginning of period | 252,243 | 218,359 | ||||||||
| Cash and cash equivalents, end of period | 213,404 | 220,867 |
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006.
The Company's head office is located at 101, 17220 Stony Plain Road NW, Edmonton, Alberta, Canada, T5S 1K6.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned, controlled and franchised retail cannabis stores in certain Canadian jurisdictions where the private sale of adult-use cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis in Canada and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.
SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 13), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's liquor retail operations are seasonal in nature. Accordingly, sales will vary by quarter based on consumer spending behaviour. The Company is able to adjust certain variable costs in response to seasonal revenue patterns; however, costs such as occupancy are fixed, causing the Company to report a higher level of earnings in the third and fourth quarters. This business seasonality results in quarterly performance that is not necessarily indicative of the year's performance. The cannabis industry is a growing industry and the Company has not observed significant seasonality as of yet.
The Company's common shares trade on the Nasdaq Capital Market under the ticker symbol SNDL and on the Canadian Securities Exchange under the symbol SNDL .
In early 2025, the U.S. administration imposed certain tariffs on imports from certain countries, including Canada, and in response, the Canadian administration imposed their own tariffs on certain imports from the United States. Canada and the United States continue ongoing negotiations on a new trade and security relationship, though the scope and terms of such negotiations and the agreements they may produce, if any, are unknown. These tariff announcements and the risk of further potential retaliatory tariffs have created uncertainty, which has permeated the economic and investment outlook, impacting current economic conditions, including such issues as the inflation rate and the global supply chain. Aside from the impact on the global economy, these tariffs may continue to impact SNDL.
SNDL is continuing to monitor the evolving situation and the impacts and potential consequences on its financial position. The Company did not experience a significant impact to its financial performance during the three months ended March 31, 2026.
2.Basis of presentation
Statement of compliance
These condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
annual consolidated financial statements for the year ended December 31, 2025. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2025.
Certain prior period amounts have been reclassified to conform to current year presentation. Specifically, changes to investments have been separated into additions to investments and principal payments from investments and change in fair value of biological assets has been separated into change in fair value of biological assets and change in fair value of inventory sold, both on the condensed consolidated interim statement of cash flows.
These financial statements were approved and authorized for issue by the board of directors of the Company (the Board ) on April 28, 2026.
3.NEW ACCOUNTING STANDARDS
Classification and Measurement of Financial Instruments Amendments to IFRS 9 and IFRS 7
On January 1, 2026, the Company adopted the amendments to IFRS 9 and IFRS 7 using the prospective application. The amendments include the following:
-Clarification on the date of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic payment system.
-Clarification and further guidance for assessing whether a financial asset meets the solely payments of principal and interest criterion.
-New disclosure requirements for certain instruments without contractual terms that can change cash flows.
-Updates to the disclosure required for equity instruments designated at FVOCI.
At March 31, 2026, there was a $5.7 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, which is reflected in the statement of financial position and statement of cash flows. The Company estimated the impact to be approximately $12.1 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, had the amendments been in effect for the annual period ending December 31, 2025.
4.Business acquisitions
On April 9, 2025, the Company announced that it had entered into an arrangement agreement (the 1CM Agreement ) with 1CM Inc. ( 1CM ) pursuant to which it would acquire 32 cannabis retail stores (the 1CM Transaction ) operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the 1CM Stores ).
Under the terms of the 1CM Agreement, the Company would acquire, with the option to assign, the 1CM Stores for total consideration of $32.2 million cash, subject to certain adjustments at the closing of the 1CM Transaction. The 1CM Stores are comprised of 2 stores in Alberta, 3 stores in Saskatchewan and 27 stores located in Ontario.
The 1CM Transaction is to be completed by way of an arrangement under the Business Corporations Act (Ontario). On June 16, 2025, 1CM announced the approval of the 1CM Transaction by 1CM shareholders. On June 18, 2025, 1CM announced that the Ontario Superior Court of Justice (Commercial List) approved the plan of arrangement involving SNDL.
On December 15, 2025, the Company announced that it had entered into an amended and restated arrangement agreement (the 1CM A&R Agreement ). Under the 1CM A&R Agreement, the parties have agreed to, among other things, complete the 1CM Transaction in two stages to align with the status of required provincial regulatory approvals. The aggregate purchase price for the 1CM Transaction has not been amended.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
On January 7, 2026, the first closing ( First Closing ) was completed and involved the purchase of 5 cannabis retail stores located in Alberta and Saskatchewan. The purchase price for the First Closing was $5.0 million cash, subject to certain adjustments at the time of the First Closing. Pursuant to the 1CM A&R Agreement, the Company had previously paid a $2.0 million non-refundable cash deposit towards the purchase price in respect of the First Closing.
The second closing ( Second Closing ) will involve the purchase of the remaining 27 cannabis retail stores, each of which are located in Ontario. The purchase price for the Second Closing will be $27.2 million cash, subject to certain adjustments at the time of the Second Closing. In addition, the outside date for completion of the 1CM Transaction has been extended from December 31, 2025 to May 31, 2026. The previously paid $1.0 million cash deposit from April 2025 will be applied towards the purchase price in respect of the Second Closing, which is still pending regulatory approval.
The purchase price allocation is not final as the Company continues to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment. The fair value of consideration paid was as follows:
| Provisional | Adjustments | Provisional | |||||||
| Cash | 5,000 | 5,000 |
The preliminary fair value of the assets and liabilities acquired was as follows:
| Provisional | Adjustments | Provisional | |||||||
| Inventory | 385 | 22 | 407 | ||||||
| Prepaid expenses and deposits | 10 | 10 | |||||||
| Right of use assets | 554 | 1,150 | 1,704 | ||||||
| Property, plant and equipment | 1,172 | 1,172 | |||||||
| Lease liabilities | (435 | ) | (870 | ) | (1,305 | ) | |||
| Total identifiable net assets acquired | 1,686 | 302 | 1,988 | ||||||
| Goodwill | 3,314 | (302 | ) | 3,012 | |||||
| 5,000 | 5,000 |
Goodwill reflects benefits arising from the acquisition that are not individually identifiable or separately recognizable, including expected operational synergies and future growth opportunities.
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, the accounting for the acquisition will be revised.
The consolidated financial statements incorporate the operations of the 5 cannabis retail stores located in Alberta and Saskatchewan commencing January 8, 2026. During the period January 8, 2026 to March 31, 2026 the Company recorded revenues of $0.9 million and a net loss of $0.2 million from the 5 cannabis retail stores. Had the First Closing closed on January 1, 2026, management estimates that for the period January 1, 2026, to January 7, 2026, revenue would have increased by $79 thousand and net loss would have increased by $17 thousand. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2026.
The Company incurred costs related to the First Closing of $0.1 million which have been included in transaction costs.
5.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Liquor retail includes the sale of wines, beers and spirits through wholly owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis products and accessories through corporate-owned, controlled and franchised retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
| Cannabis Retail | Cannabis Operations | Intersegment Eliminations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | |||||||||||||||||
| As at March 31, 2026 | ||||||||||||||||||||||||
| Total assets | 206,508 | 211,380 | 417,888 | 319,076 | 410,095 | 167,580 | 1,314,639 | |||||||||||||||||
| Three months ended March 31, 2026 | ||||||||||||||||||||||||
| Net revenue (1) | 77,345 | 29,432 | (14,954 | ) | 91,823 | 104,083 | 195,906 | |||||||||||||||||
| Gross profit | 20,352 | 5,802 | 26,154 | 26,658 | 52,812 | |||||||||||||||||||
| Operating income (loss) | 1,116 | (6,942 | ) | (5,826 | ) | (3,160 | ) | 2,038 | (2,166 | ) | (9,114 | ) | ||||||||||||
| Earnings (loss) before income tax | 554 | (7,109 | ) | (6,555 | ) | (4,572 | ) | 2,038 | (2,319 | ) | (11,408 | ) |
(1)The Company has eliminated $15.0 million for the three months ended March 31, 2026 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
| Cannabis Retail | Cannabis Operations | Intersegment Eliminations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | |||||||||||||||||
| As at December 31, 2025 | ||||||||||||||||||||||||
| Total assets | 219,462 | 211,625 | 431,087 | 324,447 | 397,537 | 182,846 | 1,335,917 | |||||||||||||||||
| Three months ended March 31, 2025 | ||||||||||||||||||||||||
| Net revenue (1) | 77,540 | 34,319 | (16,417 | ) | 95,442 | 109,472 | 204,914 | |||||||||||||||||
| Gross profit | 19,627 | 9,211 | 28,838 | 27,803 | 56,641 | |||||||||||||||||||
| Operating income (loss) (2) | 1,327 | (6,171 | ) | (4,844 | ) | (2,417 | ) | (1,601 | ) | (3,191 | ) | (12,053 | ) | |||||||||||
| Earnings (loss) before income tax (2) | 774 | (6,318 | ) | (5,544 | ) | (3,462 | ) | (1,601 | ) | (4,100 | ) | (14,707 | ) |
(1)The Company has eliminated $16.4 million for the three months ended March 31, 2025 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
(2)Recast - refer to description below
In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.
The following table presents the effect of the adjustments made to operating income (loss) and earnings (loss) before income tax for the periods indicated.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
| Cannabis Retail | Cannabis Operations | Intersegment Eliminations | Cannabis Total | Liquor Retail | Investments | Corporate | Total | |||||||||||||||||
| Three months ended March 31, 2025 | ||||||||||||||||||||||||
| Operating income (loss) as previously reported | 5,162 | (486 | ) | 4,676 | 1,980 | (1,601 | ) | (17,108 | ) | (12,053 | ) | |||||||||||||
| Adjustment to general and administrative expenses | (3,835 | ) | (5,685 | ) | (9,520 | ) | (4,397 | ) | 13,917 | |||||||||||||||
| Operating income (loss) as recast | 1,327 | (6,171 | ) | (4,844 | ) | (2,417 | ) | (1,601 | ) | (3,191 | ) | (12,053 | ) | |||||||||||
| Earnings (loss) before income tax as previously reported | 4,609 | (633 | ) | 3,976 | 935 | (1,601 | ) | (18,017 | ) | (14,707 | ) | |||||||||||||
| Adjustment to general and administrative expenses | (3,835 | ) | (5,685 | ) | (9,520 | ) | (4,397 | ) | 13,917 | |||||||||||||||
| Earnings (loss) before income tax as recast | 774 | (6,318 | ) | (5,544 | ) | (3,462 | ) | (1,601 | ) | (4,100 | ) | (14,707 | ) |
Geographical disclosure
As at March 31, 2026, the Company had non-current assets related to credit investments in the United States of $395.4 million (December 31, 2025 $385.5 million). For the three months ended March 31, 2026, share of profit of equity-accounted investees related to operations in the United States was a profit of $0.5 million (three months ended March 31, 2025 loss of $4.5 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
| As at | March 31, 2026 | December 31, 2025 | ||||
| Balance, beginning of year | 3,120 | 1,187 | ||||
| Increase in biological assets due to capitalized costs | 4,713 | 16,082 | ||||
| Net change in fair value of biological assets | 46 | 2,322 | ||||
| Transferred to inventory upon harvest | (4,910 | ) | (16,471 | ) | ||
| Balance, end of period | 2,969 | 3,120 |
Biological assets are valued in accordance with International Accounting Standard 41 Agriculture and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
The Company estimates the harvest yields for cannabis at various stages of growth. As at March 31, 2026, it is estimated that the Company's biological assets will yield approximately 11,785 kilograms (December 31, 2025 12,189
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
kilograms) of dry cannabis when harvested. During the three months ended March 31, 2026, the Company harvested 8,941 kilograms of dry cannabis (three months ended March 31, 2025 6,736 kilograms).
| As at | March 31, 2026 | December 31, 2025 | ||||
| Retail liquor | 77,216 | 75,145 | ||||
| Retail cannabis | 15,772 | 16,348 | ||||
| Harvested cannabis | ||||||
| Work-in-progress | 2,902 | 2,203 | ||||
| Finished goods | 5,434 | 4,342 | ||||
| Manufactured cannabis | ||||||
| Dried cannabis & biomass | 5,397 | 2,270 | ||||
| Work in progress | 13,871 | 12,577 | ||||
| Finished goods | 5,566 | 5,600 | ||||
| Packaging supplies and consumables | 8,824 | 8,392 | ||||
| 134,982 | 126,877 |
During the three months ended March 31, 2026, inventories of $141.5 million were recognized in cost of sales as an expense (three months ended March 31, 2025 $148.8 million).
During the three months ended March 31, 2026, the Company recognized inventory write downs of $1.4 million (three months ended March 31, 2025 $0.6 million).